Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isopropyl Alcohol SCHEMBL8447050 | 0.88 | PIK3CG (0.47) | ADORA2APIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL3692533 | 0.81 | ADORA2A (0.57) | ADORA2APIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL3660280 | 0.78 | ADORA2A (0.53) | ADORA2APIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL63822 | 0.78 | ADORA2A (0.53) | ADORA2APIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL30965441 | 0.78 | ADORA2A (0.53) | ADORA2APIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL11471050 | 0.77 | ADORA2A (0.48) | ADORA2APIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL31143797 | 0.77 | NOS1 (0.54) | NOS1DHFR | |
| SCHEMBL30435493 | 0.77 | NOS1 (0.54) | NOS1DHFR | |
| SCHEMBL64146 | 0.77 | NOS1 (0.54) | NOS1DHFR | |
| Bromide SCHEMBL11633687 | 0.76 | ADORA2A (0.52) | ADORA2APIK3CGPIK3CAPIK3CBHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691858-B2 | Kinase inhibitors and methods of use thereof | TARGEGEN, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691858-B2 | Kinase inhibitors and methods of use thereof | TARGEGEN, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691858-B2 | Kinase inhibitors and methods of use thereof | TARGEGEN, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| WO-2007127366-A2 | KINASE INHIBITORS AND METHODS OF USE THEREOF | TARGEGEN, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070259876-A1 | Kinase inhibitors and methods of use thereof | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070259876-A1 | Kinase inhibitors and methods of use thereof | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070259876-A1 | Kinase inhibitors and methods of use thereof | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259876-A1 | Kinase inhibitors and methods of use thereof | ROCK1, ADCK1, MAP3K20 | ADORA2A 803/4885PIK3CG 180/4885PIK3CA 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.